Why Amphastar Pharmaceuticals Inc’s (AMPH) Stock Is Up 4.07%

By Jenna Brashear
August 19, 2024
Featured Tickers:

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Amphastar Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding Amphastar Pharmaceuticals Inc’s stock price such as:

  • Amphastar Pharmaceuticals Inc’s current stock price and volume
  • Why Amphastar Pharmaceuticals Inc’s stock price changed recently
  • Upgrades and downgrades for AMPH from analysts
  • AMPH’s stock price momentum as measured by its relative strength

About Amphastar Pharmaceuticals Inc (AMPH)

Before we jump into Amphastar Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Want to learn more about Amphastar Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Amphastar Pharmaceuticals Inc.

Learn More About A+ Investor

Amphastar Pharmaceuticals Inc’s Stock Price as of Market Close

As of August 19, 2024, 4:00 PM, CST, Amphastar Pharmaceuticals Inc’s stock price was $46.79.

Amphastar Pharmaceuticals Inc is up 4.07% from its previous closing price of $44.96.

During the last market session, Amphastar Pharmaceuticals Inc’s stock traded between $43.96 and $45.32. Currently, there are 48.91 million shares of Amphastar Pharmaceuticals Inc stock available for purchase.

Amphastar Pharmaceuticals Inc’s price-earnings (P/E) ratio is currently at 14.3, which is low compared to the Pharmaceuticals industry median of 27.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Amphastar Pharmaceuticals Inc Stock Price History

Amphastar Pharmaceuticals Inc’s (AMPH) price is currently up 7.51% so far this month.

During the month of August, Amphastar Pharmaceuticals Inc’s stock price has reached a high of $46.87 and a low of $38.42.

Over the last year, Amphastar Pharmaceuticals Inc has hit prices as high as $65.93 and as low as $36.56. Year to date, Amphastar Pharmaceuticals Inc’s stock is up 66.99%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Amphastar Pharmaceuticals Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 16, 2024, there was 1 analyst who downgraded Amphastar Pharmaceuticals Inc’s stock and 5 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Amphastar Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Amphastar Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Amphastar Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Amphastar Pharmaceuticals Inc (AMPH) by visiting AAII Stock Evaluator.

Relative Price Strength of Amphastar Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 16, 2024, Amphastar Pharmaceuticals Inc has a weighted four-quarter relative price strength of -7.35%, which translates to a Momentum Score of 41 and is considered to be Average.

Want to learn more about how Amphastar Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Amphastar Pharmaceuticals Inc Stock Price: Bottom Line

As of August 19, 2024, Amphastar Pharmaceuticals Inc’s stock price is $46.79, which is up 4.07% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Amphastar Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
Zweig Screen: 11.3% Compared to S&P 500
at only 6.9%

Gain Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.